Bionano Genomics, Inc. - BNGO STOCK NEWS

Bionano Genomics (BNGO) has published a significant clinical study confirming the efficacy of optical genome mapping (OGM) for diagnosing facioscapulohumeral muscular dystrophy (FSHD). This study, the largest of its kind, involved 351 participants and demonstrated OGM's superior speed and accuracy compared to the traditional Southern blot analysis, with a turnaround time of just 5 days versus 11 days. The findings suggest that OGM can reliably identify mutations and improve diagnostic processes for FSHD, which affects muscle strength and function.

Bionano Genomics (Nasdaq: BNGO) announced a study revealing that combining optical genome mapping (OGM) with short-read next-generation sequencing (NGS) enhances genome analysis for lung cancer, particularly in non-small cell lung carcinoma (NSCLC). The research, published in Cell Reports, demonstrates how this combination improves detection of structural variants (SVs) and aids in discovering new oncogenes. The study highlights the vital role of OGM in identifying SVs, which are crucial for understanding cancer development.

Bionano Genomics announced that NuProbe Global has adopted its Saphyr system for optical genome mapping. This integration will enhance NuProbe’s Quantitative Amplicon Sequencing and Blocker Displacement Amplification technologies, aimed at improving genome analysis in reproductive health and oncology. The Saphyr system offers advanced detection of structural DNA variants with high resolution and user-friendly workflows, which are crucial for identifying genetic diseases and cancer. Both companies aim to enhance diagnostic accuracy and patient outcomes through this collaboration.

Bionano Genomics (Nasdaq: BNGO) announced a significant presence at the upcoming European Society of Human Genetics (ESHG) conference, with 11 customer presentations showcasing optical genome mapping (OGM) data. These presentations will span three key clinical areas: hematological malignancies, inherited genetic disorders, and solid tumor analysis, highlighting the advanced capabilities of Bionano's Saphyr® system in detecting structural variants. The virtual event runs from August 28 to August 31, 2021, and aims to enhance understanding of OGM's clinical utility compared to traditional cytogenetics methods.

Bionano Genomics reported strong financial results for Q2 2021, achieving a 226% year-over-year revenue increase to $3.9 million. This growth was driven by the expansion of the Saphyr installed base, which now totals 121 systems. Cash reserves stood at $333 million as of June 30, 2021. Key highlights include the shipment of 13 Saphyr systems, significant sales in nanochannel array flow cells, and a growing presence in global cytogenetics markets. The company is focused on enhancing market adoption and reimbursement strategies as it progresses toward its 2021 milestones.

Bionano Genomics (BNGO) announced a conference call on August 4, 2021, at 4:30 p.m. ET, to discuss its second-quarter financial results ending June 30, 2021, and recent corporate achievements. Participants can join via a toll-free line or through a live webcast. The Saphyr system, utilized for genomic analysis, continues to enhance research capabilities, aiding in diagnostics for neurodevelopmental disorders through its Lineagen business, which has conducted over 65,000 genetic tests.

Bionano Genomics (BNGO) announced a record number of 10 optical genome mapping (OGM) presentations at the Cancer Genomics Consortium (CGC) meeting from August 1-4, 2021. This year's CGC is expected to exceed 500 attendees, showcasing the increasing adoption of OGM for clinical research in solid tumors, hematological malignancies, and genetic testing. Notable presentations include discussions on the benefits of OGM over traditional methods, highlighting its sensitivity and workflow efficiency. CEO Erik Holmlin emphasized the significance of Bionano's growing presence in cancer research.

Bionano Genomics (BNGO) reports results from a University Hospitals Leuven study demonstrating the effectiveness of their Saphyr system in analyzing acute lymphoblastic leukemia (ALL). The optical genome mapping (OGM) technique showed a 100% concordance with traditional methods and reduced turnaround time from 4 weeks to 1 week. Key findings include a 50% reduction in cost per sample, a higher assay success rate, and additional pathogenic findings in 5% more cases. The study supports future OGM-based assays for leukemia and other conditions.

Bionano Genomics (Nasdaq: BNGO) presented data at the 2021 European Cytogenomics Conference, showcasing the advantages of optical genome mapping (OGM) over traditional cytogenetics in leukemia research. Key studies revealed 100% concordance in pediatric leukemia diagnoses, uncovering new clinically relevant information in 60% of cases. OGM also demonstrated improved prognostic capabilities in chronic lymphocytic leukemia, with 45% of cases benefiting from additional insights. Overall, the findings underscore OGM's potential to enhance diagnostic accuracy and treatment strategies in hematological malignancies.